A cute upper gastrointestinal bleeding (UGIB) is a common medical emergency in the United States that is associated with significant morbidity and mortality, frequent hospital admissions, and costs of more than $2 billion annually to the health care system.
disease (SRMD). Acute UGIB stemming from chronic PUD usually develops outside of the hospital setting, whereas SRMD is more likely to occur in critically ill patients during hospital admissions. 6 An imbalance between gastric acid and pepsin secretions and mucosal defense mechanisms is the shared pathophysiology leading to UBIG in chronic PUD and SRMD. Under normal physiological conditions, mucosal defense and repair mechanisms such as mucus and bicarbonate secretion, endogenous prostaglandin production, and mucosal blood flow protect gastroduodenal mucosa from destruction by gastric acid and pepsin. 5 Mucosal lesions due to chronic PUD usually result from Helicobacter pylori infection or nonsteroidal anti-inflammatory drugs. Whereas H pylori degrades the gastric mucosa through bacterial enzymes and direct gastric inflammation, nonsteroidal anti-inflammatory drugs cause direct irritation to the gastrointestinal mucosa and inhibit prostaglandin synthesis. 7 In contrast, SRMD develops in the setting of diminished defense and repair mechanisms stemming from an overwhelming stress response during critical illness and mucosal ischemia. 6 
Variceal Bleeding
Cirrhosis stemming from poison consumption, autoimmune conditions, chronic alcoholism, nonalcoholic fatty liver disease, or chronic hepatitis leads to a gradual buildup of scar tissue in the liver. These fibrotic changes alter hepatic architecture, causing an increased resistance in portal flow and subsequent development of varices to decompress the portal vein. However, as portosystemic collateral circulation develops, splanchnic vasodilation and increased cardiac output occur, worsening portal hypertension. 8 The thinnest tissue layer of all varices is found at the gastroesophageal junction, making this area more prone to rupture. Hemorrhage becomes more likely as pressure, flow, and size of varices continue to increase.
Risk Factors
Several precipitating risk factors for nonvariceal bleeding have been identified, including use of specific pharmacological agents and coexisting disease states that alter normal physiological conditions in the gastrointestinal tract (Table 1) . [4] [5] [6] [7] However, in cases of variceal bleeding the single most important predictor of hemorrhage is the size of the varices. Patients with large varices have a 15% risk of hemorrhage during the first year, compared with a risk of about 6% for patients with small varices. 4 Other identifiable risk factors are listed in Table 1 .
4-7

Initial Resuscitation
Patients with UGIB generally present with weakness, dizziness, or syncope associated with hematemesis, melena, or hematochezia. The initial evaluation should include a thorough medical history, a complete physical examination, and basic laboratory tests to assess the severity and possible location of the bleeding, as well as any underlying medical issues that may affect management of UGIB. Providers also can use these initial findings to derive risk stratification scores. The GlasgowBlatchford score or the Rockall score may be used to aid in clinical decision-making, such as timing of endoscopy or need for hospital admission, or in assessing a patient's mortality risk. 5, 9 A primary assessment should address basic resuscitation principles: assessment of airway, breathing, and circulation. Patients with altered mental status or large-volume hematemesis may need to be intubated for airway protection and to prevent aspiration. Intubation also may facilitate early endoscopy by minimizing concerns about administering sedative agents in hypotensive patients without a definitive airway. Hemodynamic assessment is central to the initial treatment of a patient with UGIB given the inherent risk of intravascular hypovolemia leading to shock and multiorgan failure due to blood loss. If patients are initially hemodynamically unstable, guideline recommendations for both variceal and nonvariceal bleeding include early resuscitation with crystalloid fluids and/or red blood cell transfusions. 4, 5, 9 To our knowledge, no randomized controlled trials have been conducted to assess the ideal volume of fluid to resuscitate an actively hemorrhaging patient; however, an isotonic crystalloid fluid, such as 0.9% sodium chloride, generally should be used as a temporizing measure until blood products are available for administration. Aggressive fluid resuscitation should be avoided in the setting of hemorrhagic shock, as it can dislodge formed clots and impede the clotting process through dilution of clotting factors. Using cold fluids may inhibit the clotting cascade. 10 In cases of suspected variceal bleeding due to cirrhosis, aggressive crystalloid resuscitation poses additional risks, including an increased rate of rebleeding, worsening ascites, or fluid accumulation at other sites. 4 Restrictive red blood cell infusion strategies are preferred in both variceal and nonvariceal bleeding, as these strategies have been found to significantly improve 6-week survival and reduce rebleeding rates.
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Patients on anticoagulation or antiplatelet therapies pose an additional concern in acute hemorrhagic situations. Warfarin is an anticoagulant commonly used for prevention of thrombus formation in atrial fibrillation, mechanical valve replacement, or venous thromboembolism. Warfarin inhibits synthesis of clotting factors II, VII, IX, and X through depleting hepatic phytonadione (vitamin K 1 ) stores. For patients on warfarin therapy who are not experiencing shock at presentation but have an elevation in international normalized ratio (INR), oral phytonadione at a dose of 5 mg is an appropriate intervention to avoid rebound coagulopathies. In severe, life-threatening cases of UGIB, phytonadione at a dose of 10 mg intravenously (IV) is preferred because of its rapid onset (1-2 hours for IV form vs 6-10 hours for oral formulations). [12] [13] [14] Intravenous administration of phytonadione may cause anaphylaxis; therefore, to minimize the risk, administration should be performed slowly at a rate of 1 mg/min. [12] [13] [14] Additionally, current practice guidelines recommend the administration of 4-factor prothrombin complex concentrate (4F-PCC) in patients receiving warfarin therapy who are experiencing serious, life-threatening bleeding with elevations in INR. 5 Four-factor PCC is preferred over administration of fresh frozen plasma because of its higher concentration of clotting factors, leading to more rapid INR correction, lower risk for allergic reactions or infection transmission, and smaller volume of administration. 12 Disadvantages of 4F-PCC use include cost (up to $10 000 per treatment), unavailability at smaller institutions, and risk of thrombosis. 12 United States Food and Drug Administration-approved dosing of prothrombin complex concentrate (human) (Kcentra; CSL Behring, King of Prussia, Pennsylvania) is based on pretreatment INR and is weightbased, ranging from 25 to 50 units/kg with a maximum dose of 5000 units. Recent evidence suggests that fixed-dose 4F-PCC at 1500 units may be as effective as the US Food and Drug Administration-approved dosing in reversing the INR of acutely hemorrhaging patients. 13 Some institutions have adopted this strategy given the significant cost savings 14 ; however, the strategy should be used with caution in obese patients or patients with severely elevated INRs, populations that may require higher doses. A follow-up INR should be obtained 30 minutes after administration to ensure adequate reversal.
14 Direct oral anticoagulants (DOACs) include therapies that directly inhibit thrombin or factor Xa, ultimately preventing the formation of fibrin clots. Currently no guidelines exist that address use of DOACs in treating patients with UGIB. Given that several DOAC therapies exist, reversal must be tailored to the specific DOAC being taken. In general, all DOACs have short half-lives, ranging from 5 to 17 hours. 12 Withholding the medication during acute bleeding may be an acceptable strategy in hemodynamically stable patients; however, further reversal may be required in patients with hemodynamic instability. 5 If a dose of the DOAC medication was taken recently, activated charcoal may be given to prevent absorption.
Idarucizumab is a reversal agent specifically for dabigatran and has been shown to reverse anticoagulant effects within minutes. Dabigatran is also the only DOAC that is dialyzable, which may be a necessary strategy if idarucizumab is not available. Andexanet alfa is a reversal agent that recently has been approved by the US Food and Drug Administration for the reversal of oral factor Xa inhibitors 15 ; however, it currently has limited availability due to manufacturing delays. For hospitals without access to andexanet alfa, administration of 4F-PCC in cases of acute bleeding while on DOAC therapy is a presumably effective strategy based on in vitro and animal studies. 12 However, this strategy should be reserved for severe, life-threatening cases of bleeding.
Administration of platelets can be considered for patients who are hemodynamically unstable and on antiplatelet therapy or are thrombocytopenic. 12 For cirrhotic patients with significant baseline coagulopathies or thrombocytopenia, guidelines recommend that fresh frozen plasma and platelets be given. However, no evidence exists to suggest that administration of PCCs is necessary or beneficial in this subset of patients unless they are receiving DOAC or warfarin therapy.
Pharmacological Management
A list of common medications used for management of UGIB is provided in Table 2 , along with dosing and administration recommendations, common adverse effects, and monitoring parameters. effect that occurs during the 72-hour infusion period, as well as an inability to maintain a gastric pH greater than 4 (the goal is greater than 6). 5, 16, 17 Therefore, H2RAs should not be used for management of acute UGIB.
Proton Pump Inhibitors
The use of PPIs is widely accepted as the standard of therapy for both nonvariceal and variceal UGIB. Both gastric acid and pepsin alter coagulation by interference with the intrinsic and extrinsic clotting pathways (impairing clot formation), promotion of fibrinolysis, and inhibition of platelet aggregation. In vitro studies have shown lack of platelet aggregation when plasma pH is less than 6.
5,16,17 Additionally, this acidic environment favors clot lysis. Proton pump inhibitors inhibit the parietal H+/K+ adenosine triphosphatase pump, thereby suppressing gastric acid production, which helps maintain a neutral pH. 5, 16, 17 Time of initiation varies depending on the indication for use. For use in nonvariceal bleeding, studies and meta-analyses have shown no benefits with regard to mortality, rebleeding rates, or need for surgical intervention if PPIs are used before endoscopy. 17, 18 In patients with active bleeding, or if the type of UGIB is unknown (variceal vs nonvariceal), PPI therapy can be started before endoscopy despite the lack of evidential benefit. Therapy should be discontinued in these patients after endoscopy has been completed, unless there is a source (ulcers and erosions) that would benefit from continuation of therapy. 5, 17, 18 When PPIs are used for management of variceal bleeding, the recommendation is to begin therapy as soon as the patient arrives at the hospital; studies have indicated benefits such as reduction of need for surgical intervention or transfusions and reduced rates of rebleeding when PPI therapy is initiated before endoscopy. 4, 19 The dosing of PPI therapy consists of administering a bolus of 80 mg IV followed by a continuous infusion of 8 mg/h. 4, 5, [17] [18] [19] [20] This dosing regimen has been studied with multiple PPI formulations (pantoprazole, omeprazole, esomeprazole) and is appropriate for all PPIs. The continuous infusion should be continued for 72 hours after endoscopy. Once the initial 72 hours of therapy has been completed, twice-daily oral or IV PPI use, if appropriate for the patient, is recommended to continue for 11 to 14 days, at which time a daily PPI may be instituted. 16, 21 Alternate PPI dosing strategies have been evaluated for the management of UGIB. 20 A meta-analysis investigated whether twicedaily IV boluses of PPIs would be just as effective as a continuous infusion. 20 Results of this analysis showed twice-daily injections to be just as efficacious as a single bolus followed by a continuous infusion. 20 Although both of these dosing strategies are effective, continuous infusion dosing was associated with a reduction of approximately 3% in recurrence of ulcer bleeding at 7 days. 20 On the basis of these findings, the European guidelines recommend continuous infusion over intermittent PPI use; the American guidelines have not been updated since the publication of these outcomes. 17, 19 Concerns about use of PPIs include an increased incidence of Clostridium difficile diarrhea and pneumonia. By inhibiting gastric acid secretion (one of the body's natural defenses against infection), PPIs create an environment that promotes bacterial growth that can translocate into the lungs or allow further growth in the gastrointestinal tract. Several studies and meta-analyses have been published with conflicting results, most demonstrating no increased incidence of either infectious complication. [22] [23] [24] [25] However, as critically ill patients are vulnerable and at increased infection risk at baseline, care should be taken to minimize and discontinue PPI therapy as soon as possible. 17 Of most concern are drug interactions and potential reduced absorption of other pertinent medications the patient may be receiving. Proton pump inhibitors act as major substrates of CYP2C19 and minor substrates of CYP2D6 and CYP3A4. The efficacy and metabolism of PPIs can be altered if they are given concomitantly with inhibitors of CYP2C19, CYP2D6, and CYP3A4, or with inducers of CYP219 and CYP3A4. Proton pump inhibitors will reduce absorption of some medications that require an acidic environment for absorption, including aspirin, ketoconazole, atazanavir, some cephalosporin antibiotics, and fluoroquinolone antibiotics. 26 
Somatostatin Analogues and Vasopressin
Several vasoactive options have been studied for gastrointestinal hemorrhage, including vasopressin, octreotide, and terlipressin. Terlipressin is a synthetic analogue of vasopressin and has shown significant benefits with improved control of bleeding and survival compared with placebo. Terlipressin is the only pharmacotherapeutic agent to have shown mortality benefit; however, it is not yet available in the United States. 4, 19 Octreotide and vasopressin are currently the only available options in the United States.
Vasopressin is a potent splanchnic vasoconstrictor with the ability to decrease portal pressure and portal venous flow. Although vasopressin has several beneficial mechanisms, limiting factors including cardiac, peripheral, and bowel ischemia, and increased incidence of arrhythmias, hypertension, and fluid retention have made it a last-line pharmacological option for management of UGIB. Concomitant use of nitrates enhances the efficacy and safety of vasopressin therapy, although the combined side effect profile reported is greater than with somatostatin analogues (eg, octreotide) or with terlipressin. 4, 19 Vasopressin is dosed at a rate of 0.2 to 0.4 units/min and can be titrated up to a maximum dose of 0.8 units/ min. 4 Nitroglycerin should be given in conjunction with vasopressin to counter the vasoconstrictive effects, at a rate of 40 μg/min titrated to a maximum of 400 μg/min to maintain systolic blood pressure greater than 90 mm Hg. 4 Octreotide is a somatostatin analogue that, when given at pharmacological doses, offers benefit in UGIB through inhibition of secretion of several substances, including serotonin, gastrin, insulin, and, most importantly, glucagon, which is a vasodilatory peptide, resulting in splanchnic vasoconstriction and a reduction in portal venous flow. The inhibition of these secretions reduces variceal pressure, thereby improving the ability to gain control of the variceal hemorrhage. 4, 19, 27 The primary indication and benefit of octreotide is in the management of variceal bleeding. Studies examining octreotide use in nonvariceal bleeding have shown no benefit; however, octreotide may be initiated if the source of bleeding is unknown or the patient has a questionable history of alcoholism or cirrhosis. 4, 18, 19, 27 Additionally, if endoscopy is not readily available or the patient has another issue prolonging time to endoscopic intervention, octreotide may be an appropriate alternative to initiate in the interim. 4, 18, 19, 27 A Cochrane review assessing octreotide therapy in variceal bleeding found no benefit regarding mortality or risk of rebleeding; however, significant benefit was shown in reducing the amount of blood transfused (roughly one-half unit of blood saved per patient) and the number of patients not achieving initial hemostasis. 28 The authors concluded that a large trial with thousands of patients enrolled would be needed to detect an actual mortality benefit. 28 Guidelines currently recommend an initial IV bolus of 25 to 100 μg followed by a continuous infusion of 25 to 50 μg/h for 2 to 5 days. 4, 8, 19 Octreotide has a benign adverse effect profile; however, bradycardia, palpitations, peripheral edema, hypertension, fatigue, headache, dizziness, and hyperglycemia may occur with its use.
Antibiotics
Patients with cirrhosis who present with UGIB are at elevated risk for developing severe bacterial infections within their ascitic fluid that may translocate into the blood and/or other organ systems. These infections are associated with increased incidence of recurrent variceal hemorrhage and mortality. For these reasons, a short course of prophylactic antibiotics should be initiated immediately to help reduce the risk of death and the incidence of bacterial infections. 4, 19, 27 Norfloxacin, 400 mg orally twice a day for 7 days, has been recommended on the basis of previous studies; however, ceftriaxone, 1 g IV daily, was compared with norfloxacin for this indication and was found to be superior in preventing bacterial infections. 29 For cirrhotic patients who present with UGIB, ceftriaxone, 1 g IV, should be initiated and continued for 7 days.
Helicobacter pylori is a prominent cause of UGIB resulting from ulcers. Serum testing for H pylori is recommended during the acute phase of UGIB; however, caution should be exercised regarding the validity of the results. Medications used for treatment of patients with acute UGIB (antibiotics and PPIs) may cause false-positive results. 17, 18 If initial testing results are negative, a second test is recommended after bleeding cessatin to rule out a false-negative result. Repeat testing should be performed at least 2 weeks after cessation of PPI therapy. 17, 18 All patients with a positive test result should receive a repeat test 1 month after treatment to ensure eradication of the bacteria. A meta-analysis published in 2004 found that H pylori eradication significantly reduced recurrent bleeding compared with antisecretory therapy alone. 30 A patient with a positive serum result should be treated with triple therapy: PPI, amoxicillin, and clarithromycin. In areas with prevalent antibiotic resistance, quadruple therapy with a PPI, bismuth subsalicylate, metronidazole, and tetracycline is recommended.
Conclusion
Although mortality rates remain high for UGIB, specifically variceal bleeding, no significant advances or changes have occured in the past decade regarding initial resuscitation and pharmacological management options. Proton pump inhibitors remain the mainstay of treatment for patients with UGIB, with the addition of somatostatin analogues recommended due to variceal bleeding. Histamine receptor antagonists are not recommended given available evidence of their inferiority to PPIs. Helicobacter pylori eradication is effective and may help reduce the incidence of recurrent UGIB. Prompt identification and treatment of UGIB is essential to maximize patient survival and minimize complications.
